Eli Lilly Sues Six Companies for Selling Versions of its Experimental Weight Loss Drug Retatrutide, in Effort to Crack Down on Vast Illicit Market

Eli Lilly said Wednesday it is suing six companies selling versions of its experimental weight-loss drug retatrutide, calling it the beginning of a concerted effort to crack down on a vast illicit market.

That market has boomed even though retatrutide is still being studied in clinical trials and hasn’t been approved by the Food and Drug Administration as safe and effective. Federal law prohibits the commercial sale of unapproved drugs, but many telehealth firms, clinics and peptide vendors online have decided to offer the next-generation drug anyway, as promising results from Eli Lilly’s trials have fueled a craze for it on social media.

Read more at CBS News